Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 70/100

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Monday, June 2, 2025 1 min read
Key Takeaway: Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will participate in the 46th Annual Global Goldman Sachs Health Care Conference on June 11, 2025. The company focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). Their lead medication, Rezdiffra, is the first FDA-approved therapy for MASH with moderate to advanced fibrosis. A live webcast of the presentation will be available, along with a replay afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals is presenting at a prominent healthcare conference.
  • The company is focused on an under-served condition, MASH.
  • Rezdiffra is the first FDA-approved therapy for treating MASH with fibrosis.

Full Press Release Details

CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.
Tina Ventura, IR@madrigalpharma.com
Christopher Frates, media@madrigalpharma.com

Tags

Frequently Asked Questions

When is Madrigal Pharmaceuticals presenting at the conference?

Madrigal Pharmaceuticals will present on June 11, 2025, at 10:40 A.M. EDT.

How can I access the webcast for the presentation?

The presentation can be accessed through Madrigal's Investor Relations page.

What condition does Madrigal Pharmaceuticals focus on?

Madrigal focuses on metabolic dysfunction-associated steatohepatitis (MASH).

What is Rezdiffra and its significance?

Rezdiffra is the first FDA-approved drug for treating MASH with advanced fibrosis.

What trial is currently ongoing for Rezdiffra?

An ongoing Phase 3 trial is assessing Rezdiffra for compensated MASH cirrhosis.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals MASH Rezdiffra Goldman Sachs
Last updated: Jun 2, 2025